Can LIFT and NorthStar move Lu-177-LT17 into the next radioligand therapy frontier?
Find out how LIFT and NorthStar’s Lu-177-LT17 partnership could advance radioligand therapy for cancer bone disease today!
Can Brenus Pharma crack the cold-tumor problem in metastatic colorectal cancer?
Find out how Brenus Pharma’s STC-1010 FDA IND acceptance could reshape MSS colorectal cancer immunotherapy development.
Can AI help Biomunex find better bispecific antibody targets in cancer?
AI may speed cancer drug discovery, but Biomunex’s bigger test is whether smarter target pairing can translate into stronger immunotherapies.
Can United Immunity revive macrophage cell therapy after Carisma’s reset?
Macrophage cell therapy has promise but painful execution risk. United Immunity’s Carisma deal tests whether in vivo CAR-M can scale.
Is Can-Fite BioPharma Ltd. building a differentiated niche in late-line pancreatic cancer therapy
Is Can-Fite BioPharma Ltd. carving a niche in pancreatic cancer? Explore how namodenoson’s Phase 2a data could reshape late-line treatment strategies.
AbbVie Inc. secures strategic option on Kestrel Therapeutics Inc. amid KRAS innovation race
A new pan-KRAS approach enters Phase 1 backed by AbbVie Inc. Discover the implications for oncology pipelines and KRAS-driven cancers.
Can logic-gated CAR T therapies finally crack solid tumors? A2 Biotherapeutics shares early ASCO data
A2 Biotherapeutics shares EVEREST-2 CAR T data at ASCO 2026. Find out what this means for solid tumor therapy and next-gen cell treatments.
AVZO-021 at ASCO 2026: what updated Phase 1 results could reveal about Avenzo Therapeutics’ CDK2 strategy
Avenzo Therapeutics will present updated AVZO-021 Phase 1 data at ASCO 2026. Read why the CDK2 story could matter for breast cancer and beyond.
Why CStone Pharmaceuticals’ CS5007 may be the most important asset in its AACR 2026 antibody-drug conjugate update
CStone Pharmaceuticals unveiled three ADC programs at AACR 2026. Read what CS5007, CS5006, and CS5008 could mean for oncology development.
Salubris Biotherapeutics expands JK06 data at AACR 2026 with encouraging responses in difficult solid tumors
Salubris Biotherapeutics’ JK06 showed early AACR 2026 activity in NSCLC and breast cancer. Read what it could mean for the 5T4 ADC race.